MedTrace Logo

Pioglitazone Special Drug Use Surveillance "Metabolic Syndrome in Patients With Type 2 Diabetes Mellitus"

NCT02002975 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 18223

Last updated 2019-01-24

Study results available
· View outcomes & findings →

Summary

The purpose of this survey is to determine the onset of new cerebral and cardiovascular events and changes in metabolic syndrome parameters in patients with type 2 diabetes mellitus on long-term pioglitazone (Actos Tablets) treatment.

Conditions

Interventions

DRUG

Pioglitazone

Pioglitazone tablets

Sponsors & Collaborators

Principal Investigators

  • Study Director · Takeda

Eligibility

Min Age
20 Years
Max Age
74 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-10-16
Primary Completion
2013-06-30
Completion
2013-06-30

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02002975 on ClinicalTrials.gov